Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TherO2-MBC Study in HER2-positive metastatic breast cancer
2024-516576-15-00Phase 3Authorised
- Sponsor
- Unicancer
- Start
- Oct 2025
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing TherO2-01S22 add-on arm with Placebo add-on control arm (2 arms). Primary endpoint: Objective response rate. Planned start Oct 2025; status: authorised.
02
Drugs
thero2-01s22
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2024-516576-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516576-15-00.